

# Introduction to microarrays

*Overview*

*The analysis process*


*Limitations*

*Extensions (NGS)*




# Outline

- An overview (a review) of microarrays
- Experiments with microarrays
- The data analysis process
- Microarray limitations
- From microarrays to Next generation sequencing




# cDNA microarrays: Overview



To visualize an animation go to:

<http://www.bio.davidson.edu/courses/genomics/chip/chip.html>

# Oligo (Affy) microarrays: overview





# Comparison between two types

## **cDNA Microarrays**

### ADVANTAGES

- Cheaper (not anymore)
- Flexibility (customizable)
- High signal intensity (long sequences)

### DISADVANTAGES

- Lower reproducibility
- Cross-hybridization (low specificity)
- Need more manual handling (possibility of contamination)

## **Oligonucleotide Microarrays**

### ADVANTAGES

- Quick and robotic manufacturing
- Higher Reproducibility
- High specificity (short sequences)
- Use many probes / gene


### DISADVANTAGES

- Requires more specialized equipment
- Expensive
- Less flexible (genes on the chip cannot be selected)




# Experiments with microarrays

# Types of studies (1): *Class comparison*





Nature Reviews | Neuroscience







# Types of studies (2): *Class discovery*




# Types of studies (3): *Class prediction*



# The microarray analysis process




# (0) Experimental design



- Variability
  - Systematic
    - Calibrate/Normalize
  - Random
    - Experimental design
    - Statistical inference
- Must decide about:
  - Replicates
  - Batches (“Batch effect”)
  - Pools ...

Awful design :-)				Balanced design :-)			
Sample	Treatment	Sex	Batch	Sample	Treatment	Sex	Batch
1	A	Male	1	1	A	Male	1
2	A	Male	1	2	A	Female	2
3	A	Male	1	3	A	Male	2
4	A	Male	1	4	A	Female	1
5	B	Female	2	5	B	Male	2
6	B	Female	2	6	B	Female	1
7	B	Female	2	7	B	Male	1
8	B	Female	2	8	B	Female	2

# (1) Image obtention



Input: Microarrays

Output:

Images (1/chip)

Information for each  
individual probe


Data to be used for

Quality control

Preprocess

Summarization

## (2) Quality control



Input:

Images (.CEL, ...)

Process

Diagnostics


Quality checks

Output:

Plots

Quality indexes

# (3) Preprocess



Input:

Images

Process

Noise filtering

Normalization

Summarization

Filtering


Output:

Expression marix



# (4) Exploration

	C01-001.CEL	C02-001.CEL	C03-001.CEL
1415670_at	8.954387	9.088924	8.833863
1415671_at	10.700876	10.639307	10.610953
1415672_at	10.377266	10.510106	10.461701
1415673_at	7.320335	7.252635	7.112313
1415674_a_at	8.381129	8.332256	8.393718
1415675_at	8.120937	8.082713	8.051514
1415676_a_at	10.322229	10.287371	10.282812
1415677_at	9.038344	8.979641	8.905711



Input

Expression matrix

Process

PCA, Cluster, MDS

2D/3D plots

Output


Visualizations

Possible unexplained groupings (e.g. batch effect) detected



# (5) Statistical analysis (i): *Selecting differentially expressed genes*

	C01-001.CEL	C02-001.CEL	C03-001.CEL
1415670_at	8.954387	9.088924	8.833863
1415671_at	10.700876	10.639307	10.610953
1415672_at	10.377266	10.510106	10.461701
1415673_at	7.320335	7.252635	7.112313
1415674_a_at	8.381129	8.332256	8.393718
1415675_at	8.120937	8.082713	8.051514
1415676_a_at	10.322229	10.287371	10.282812
1415677_at	9.038344	8.979641	8.905711



Input:

Expression matrix

Analysis models

Process

t-tests, ANOVA

P-value adjustment

Output


Gene lists

Fold change, p.values

Plots

Expression profiles

## (5) Statistical analysis (ii): *Building and validating a predictor*



Input:

Expression matrix

Process

Variable selection

Model fitting

Validation



Output

Predictive models

Measures of sensitivity and  
reproducibility

# (6) Biological significance

ProbeSet	gene	ID	logFC
1450826_a_at	Saa3	1450826_a_at	4.911
1457644_s_at	Cxcl1	1457644_s_at	4.286
1415904_at	Lpl	1415904_at	-4.132
1449450_at	Ptges	1449450_at	5.164
1419209_at	Cxcl1	1419209_at	5.037
1416576_at	Socs3	1416576_at	3.372
1450330_at	Il10	1450330_at	4.519
1455899_x_at	Socs3	1455899_x_at	3.648
1419681_a_at	Prok2	1419681_a_at	3.709
1436555_at	Slc7a2	1436555_at	3.724



Input

Gene lists

Process

GEA, GSEA,

Network analysis

Output:

Relevant GO or KEGG terms

Relevant pathways

Networks



# Microarray limitations

# All that glitters is not gold

## THE LANCET

Search for  in   [Advance](#)

[Home](#) | [Journals](#) | [Collections](#) | [Audio](#) | [Conferences](#) | [Education](#) | [Resource Centres](#) | [For Authors](#)

The Lancet, [Volume 365](#), [Issue 9458](#), Pages 454 - 455, 5 February 2005  
doi:10.1016/S0140-6736(05)17878-7 [Cite or Link Using DOI](#)

[< Previous Article](#) | [Next Article >](#)

### Microarrays and molecular research: noise discovery?

[John PA Ioannidis](#) [a](#) [b](#) [c](#) 

The promise of microarrays has been of apocalyptic dimensions. As put forth by one of their inventors, “all human illness can be studied by microarray analysis, and the ultimate goal of this work is to develop effective treatments or cures for every human disease by 2050”. [1](#) All diseases are to be redefined, all human suffering reduced to gene-expression profiles. Cancer has been the most common early target of this revolution [2](#) and publications in the most prestigious journals have heralded the dis ...



**PLOS** MEDICINE

a peer-reviewed open-access journal published by the Public Library of Science

[Home](#) [Browse Articles](#) [About](#) [For Readers](#) [For Authors and](#)

**nature**  
REVIEWS **DRUG  
DISCOVERY**



### An array of problems

Despite the huge amount of published microarray data in cancer, little is being converted into clinical practice. Validating initial data is proving to be a key challenge, reports SIMON FRANTZ.

EDITORIAL


OPEN

## Why Bigger Is Not Yet Better: The Problems with Huge Datasets

# An array of problems?

- ▶ By the middle of the decade some claims against microarrays were raised.
  - Lack of reproducibility between studies.
  - Few coincidences between gene lists.
  - Predictions on new test data did not reproduce those in training data.
  - ...
  - The step to the clinic always waiting.

# Que no estamos tan mal...



## **Critical Review of Published Microarray Studies for Cancer Outcome and Guidelines on Statistical Analysis and Reporting**

Alain Dupuy, Richard M. Simon



# So what?

- Systematic reviews showed that the main problem was not the technology but inappropriate application of (statistical) methodology.
- Large quality control studies (MAQC) were promoted to investigate reliability and applicability of the technique.



# Some consensus (Allison 2006)

## ► Design

- Biological replication is essential
- There is strength in numbers: power & sample size
- Pooling biological samples can be useful

## ► Selecting differentially expressed genes

- Using FC alone as a differential expression test is not valid
- 'Shrinkage' is a good thing
- **FDR is a good alternative to conventional multiple-testing approaches**

## ► Classification and Prediction

- Unsupervised classification is overused
- Unsupervised classification should be validated using resampling-
- Supervised-classification requires independent cross-validation



# In summary

- ▶ Microarrays have some reasonable limitations.
  - ▶ Some, such as noise or restriction to known sequences, are intrinsic and cannot be removed.
  - ▶ Other issues can be solved using appropriate data analysis methods.
- ▶ Studies suggest that, ***if well used***, it is a reliable technique that yields reliable reproducible results.
- ▶ Statistics has made important contributions and has benefited from the problems raised by microarrays.
- ▶ ***However*** the step from bedside to clinic is taking much longer than expected.

# Is microarray time over?

## InSightu

a nature network blog by Anthony Fejes

[HOME](#)

ARCHIVE

## ABOUT

## POLICY

## Announcing the death of the Micro-array

Bookmark in Connotea

Ok, here it is: Micro-arrays are dead. In the fish head someone tossed into the compost won't be picked up till this Tuesday waiting to be done.

## nature methods

## Techniques for life scientists and chemists

## Access

**To read this story in full you will need to login or make a payme**

[nature.com](#) > [Journal home](#) > [Table of Contents](#)

## NEWS AND VIEWS

*Nature Methods* **5**, 585 - 587 (2008)  
doi:10.1038/nmeth0708-585

## The beginning of the end for microarrays?

Jay Shendure<sup>1</sup>



1. Jay Shendure is in the Department of Genome Sciences, University of Washington, Seattle, Washington 98195, USA.  
e-mail: [shendure@u.washington.edu](mailto:shendure@u.washington.edu)

Two complementary approaches, both using next-generation sequencing, have successfully tackled the scale and the complexity of mammalian transcriptomes, at once revealing unprecedented detail and allowing better quantification.

## ARTICLE LINKS

- ▶ Figures and tables
- SEE ALSO**
- ▶ Article by Cloonan *ET AL.*
  - ▶ Article by Mortazavi *ET AL.*

## ARTICLE TOOLS

-  [Send to a friend](#)
-  [Export citation](#)

## naturenews

[nature news home](#)[news archive](#)**specials**

## opinion

## features

news blog

[comments on this story](#)

Published online 15 October 2008 | *Nature* **455**, 847 (2008) |  
doi:10.1038/455847a

## News


## The death of microarrays?

**High-throughput gene sequencing seems to be stealing a march on microarrays. Heidi Ledford looks at a genome technology facing intense competition.**

Heidi Ledford

Faster, cheaper DNA sequencing technology is revolutionizing the burgeoning field of personal genomics. But it





# Next generation sequencing



The future is here, now







# Next generation Sequencing

- By the middle decade new technologies consolidated allowing the massive production of tens of millions of short sequencing fragments.
- These techniques could be used to
  - Deal with similar problems than microarrays,
  - But also with many other.
- “Again” they raised the promise of personalized medicine..




# A CSI approach to gene selection (again)

- A crime has been committed (immune response)
- You're CSI –Horatio Fisher- and want to find who's responsible for this.
- Let's see how you would act ...
  - In the old times,
  - In the microarray age,
  - In the next generation age.

# In the old times ...

- You would chase the “Usual Suspects” and make an in deep interrogation.
  - If guilty you might make them talk,
  - But if not you might miss the bad guy.
- *That is looking at specific genes may yield great or awful results.*





# In the microarray age...

- You have the census of most people and their fingerprints.
  - If you find a fingerprint in your database that is clean enough you may find the bad guy.
    - What about bad prints?
    - What about those who are not censused.
    - And those no-fingerprints?
- *That is you may look at all known genes but you*
  - *do it Indirectly and noisily*
  - *miss genes/forms that are uncensused.*



# Why is sequencing different?

- If the crime scene had had cameras you would have directly known who the criminal was.
- *Sequencing allows you to access **everything***
  - *Known and unknown forms are sequenced.*
  - *The technique is less noisy and the resolution higher.*





To be continued ...